Enveric Biosciences Elevates EB-003 To Lead Development Candidate, Provides Strategic Outlook And Pipeline Update
Enveric Biosciences Elevates EB-003 To Lead Development Candidate, Provides Strategic Outlook And Pipeline Update
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds
EB-003是一種新型的神經可塑性分子，旨在治療嚴重的心理健康障礙，而不會產生通常與致幻劑基化合物相關的幻覺效應。
Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025
Enveric正在推進EB-003的臨床前開發，預計在2025年初就進行IND會議。
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the Company is prioritizing the development of EB-003, its first-in-class approach to address difficult-to-treat mental health disorders. EB-003 and other neuroplastogens developed by Enveric are designed to promote neuroplasticity without inducing hallucinations, a hallmark side effect of many psychedelic and psychedelic-inspired compounds. Enveric is currently advancing pre-clinical development activities for EB-003 and targeting a Pre-IND meeting with the U.S. Food and Drug Administration (FDA) for early 2025.
Enveric Biosciences（納斯達克：ENVB）（“Enveric”或“公司”），一家致力於開發新型神經可塑性小分子治療抑鬱症、焦慮症和成癮性障礙的生物技術公司，今天宣佈，該公司正在優先發展其首個心理健康障礙的新型療法EB-003。Enveric開發的EB-003和其他神經可塑性物質旨在促進神經可塑性，而不會引起許多致幻劑和致幻劑類藥物引起的幻覺等典型副作用。Enveric目前正在推進EB-003的臨床前開發工作，並計劃在2025年初與美國食品和藥物管理局（FDA）進行IND會議。